Adaptimmune Therapeutics Plc Overview

Adaptimmune Therapeutics Plc Research & Development

Research & Development expenses for ADAP.

Quarterly R&D Expenses

$22.98M

↓ 46.39% YoY

As of Jun 30, 2025

Annual R&D Expenses (TTM)

$125.24M

↓ 18.19% YoY

Trailing 12 months ending Jun 30, 2025

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin